The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate
Abstract
PURPOSE: To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa. PATIENTS AND METHODS: Patients with SCPCa (pure or mixed), measurable disease, good organ function, and no prior treatment with doxorubicin, etoposide, or cisplatin were treated every 4 weeks with doxorubicin 50 mg/m 2 as a 24-hour intravenous (IV) infusion followed by etoposide 120 mg/m 2/d and cisplatin 25 mg/m 2/d IV on days 2 to 4. RESULTS: Thirty-eight patients (36 assessable for response) were treated for a median of four cycles. Twenty-nine (81%) of 36 patients had prior hormonal therapy. Study patients had visceral metastases, lytic bone disease, and relatively low serum prostate-specific antigen (PSA). We observed 22 partial responses (response rate, 61% in an intent-to-treat analysis); toxicity was severe (grade 3 or 4 neutropenia 100%, thrombocytopenia 66%, mucositis 21%, and infection 68%). Three patients died of toxicity. Median time to progression and overall survival time were 5.8 months and 10.5 months, respectively. Performance status, serum albumin, and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) were predictors of survival. CONCLUSION: SCPCa presents unique clinicopathologic features. Addition of doxorubicin to the etoposide/cisplatin regimen caused higher toxicity in this patient population and failed to improve outcome. Given these results, we do not recommend further development of this regimen for patients with SCPCa. Improvement in therapy will come from understanding the biology of SCPCa progression and integrating new targeted therapies into the treatment of SCPCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The migration of neural crest cells to the wall of the digestive tract in avian embryo
Douarin, N. M. L., & Teillet, M.-A. (1973) · Development · doi:10.1242/dev.30.1.31 · Cited by 841
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Bonkhoff, H., & Remberger, K. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199602)28:2<98::aid-pros4>3.0.co;2-j · Cited by 416
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
Kevin Kelly, W., & Scher, H. I. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36163-3 · Cited by 349
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson, J. B., Chan‐Tack, K. M., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996) · PubMed · Cited by 333
Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases
Tětu, B., Ro, J. Y., Ayala, A. G., Johnson, D. E., Logothetis, C. J., & Ordonez, N. G. (1987) · Cancer · doi:10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x · Cited by 278
Self-citationPapandreou, C. N., Usmani, B., Geng, Y., Bogenrieder, T., Freeman, R., Wilk, S., Finstad, C. L., Reuter, V. E., Powell, C. T., Scheinberg, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-050 · Cited by 277
Self-citationEmbryology of the diffuse neuroendocrine system and its relationship to the common peptides.
Pearse, A. G. E., & Takor, T. T. (1979) · PubMed · Cited by 231
Kaplan, P. J., Mohan, S., Cohen, P., Foster, B. A., & Greenberg, N. M. (1999) · PubMed · Cited by 228
Pienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., & Flaherty, L. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2005 · Cited by 220
Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., & Curley, T. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37426-8 · Cited by 200
Oesterling, J. E., Hauzeur, C. G., & Farrow, G. M. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37390-1 · Cited by 192
Reile, H., Armatis, P. E., & Schally, A. V. (1994) · The Prostate · doi:10.1002/pros.2990250105 · Cited by 166
Chemotherapy for Small Cell Carcinoma of Prostatic Origin
Amato, R. J., Logothetis, C. J., Hallinan, R., Ro, J. Y., Sella, A., & Dexeus, F. H. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37427-x · Cited by 164
Self-citationDo neuroendocrine cells in human prostate cancer express androgen receptor?
Krijnen, J. L. M., Janssen, P. J. A., de Winter, J. A. R., van Krimpen, H., Schröder, F. H., & van der Kwast, T. (1993) · Histochemistry and Cell Biology · doi:10.1007/bf00268938 · Cited by 155
Bondy, C. A., & Lee, W. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb26203.x · Cited by 139
Sella, A., Kilbourn, R. G., Amato, R. J., Bui, C., Zukiwski, A. A., Ellerhorst, J. A., & Logothetis, C. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.683 · Cited by 121
Self-citationSALMON AND HUMAN CALCITONIN-LIKE PEPTIDES COEXIST IN THE HUMAN THYROID AND BRAIN
Fischer, J. A., Tobler, P. H., Henke, H., & Tschopp, F. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-6-1314 · Cited by 105
Helpap, B., Köllermann, J. W., & Oehler, U. (1999) · Urologia Internationalis · doi:10.1159/000030376 · Cited by 89
Ellerhorst, J. A., Tu, S., Amato, R. J., Finn, L., Millikan, R. E., Pagliaro, L. C., Jackson, A., & Logothetis, C. J. (1997) · PubMed · Cited by 79
Self-citationNagaoka, I., Someya, A., Iwabuchi, K., & Yamashita, T. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80208-k · Cited by 24
Cited by
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 572
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Epstein, J. I., Amin, M. B., Beltran, H., Lotan, T. L., Mosquera, J.-M., Reuter, V. E., Robinson, B. D., Troncoso, P., & Rubin, M. A. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000208 · Cited by 569
Self-citationPlatinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Self-citationPC3 is a cell line characteristic of prostatic small cell carcinoma
Tai, S., Sun, Y., Squires, J. M., Zhang, H., Oh, W. K., Liang, C., & Huang, J. (2011) · The Prostate · doi:10.1002/pros.21383 · Cited by 438
Clinical features of neuroendocrine prostate cancer
Conteduca, V., Oromendia, C., Eng, K. W., Bareja, R., Sigouros, M., Molina, A., Faltas, B. M., Sboner, A., Mosquera, J. M., Elemento, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.011 · Cited by 356
Metadata
- Authors
- Papandreou, C. N., Daliani, D. D., Thall, P. F., Tu, S.-M., Wang, X., Reyes, A., Troncoso, P., & Logothetis, C. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-07-15
- Volume
- 20
- Issue
- 14
- Pages
- 3072-3080
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2015624466
- Cited by
- 286
- References
- 28
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.